Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B2d3e396a0782f0bfafa202cc4ce8a709> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B2d3e396a0782f0bfafa202cc4ce8a709 NCIT_P378 "NCI" @default.
- B2d3e396a0782f0bfafa202cc4ce8a709 type Axiom @default.
- B2d3e396a0782f0bfafa202cc4ce8a709 annotatedProperty IAO_0000115 @default.
- B2d3e396a0782f0bfafa202cc4ce8a709 annotatedSource NCIT_C68814 @default.
- B2d3e396a0782f0bfafa202cc4ce8a709 annotatedTarget "A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity." @default.